Pain News and Research

Latest Pain News and Research

Positive updated interim data from Exelixis’ cabozantinib phase 2 trial on CRPC

Exelixis, Inc. today reported positive updated interim data from an ongoing phase 2 trial of cabozantinib in men with metastatic castration-resistant prostate cancer (CRPC) and bone metastases.

6 Jun 2012

Lilly announces final results from ALIMTA Phase III study on NSCLC

Final results from PARAMOUNT, a Phase III study of ALIMTA (pemetrexed for injection) in the continuation maintenance setting, demonstrated improved overall survival in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) treated with ALIMTA continuation maintenance, according to data announced today by Eli Lilly and Company.

5 Jun 2012

Statisticians devise new predictive algorithm for future medical conditions

Analyzing medical records from thousands of patients, statisticians have devised a statistical model for predicting what other medical problems a patient might encounter.

5 Jun 2012

Preoperative breast cancer pain involves an inflammatory process

Researchers from the University of California San Francisco studied a sample of women scheduled for breast cancer surgery and sought to determine the occurrence rate for preoperative breast pain, describe characteristics of the pain, evaluate the demographic and clinical variation in the women with preoperative pain, and assess the role of in pro-and anti inflammatory cytokine genes.

5 Jun 2012

Cannabinoid therapy helps provide effective analgesia for cancer patients with pain

An investigational cannabinoid therapy helped provide effective analgesia when used as an adjuvant medication for cancer patients with pain that responded poorly to opioids, according to results of a multicenter trial reported in The Journal of Pain, published by the American Pain Society.

5 Jun 2012

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation today announced results from a study of ABRAXANE(paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in patients with resectable pancreatic cancer.

5 Jun 2012

Positive results from BioSpecifics’ XIAFLEX Phase III clinical program on Peyronie's disease

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in Europe and Eurasia, today announced positive top-line results from the IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) Phase III clinical program of XIAFLEX for the treatment of Peyronie's disease, which was conducted by BioSpecifics' partner Auxilium Pharmaceuticals, Inc.

5 Jun 2012

ProStrakan, Orexo reconfigure commercial rights to Abstral

Orexo AB and ProStrakan Group plc jointly announce today that the companies have reconfigured the commercial rights to the product, Abstral, in various territories worldwide.

4 Jun 2012

AcelRx completes private placement of common stock

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, announced today that it completed its previously announced private placement of common stock and warrants to purchase common stock on June 1, 2012.

4 Jun 2012

First Edition: June 4, 2012

Today's headlines include the latest news on implementation of the health law, on the pending Capitol Hill effort to repeal the medical device tax and reports from the states.

4 Jun 2012

Positive results from Auxilium’s XIAFLEX phase III studies on Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive top-line results from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).

4 Jun 2012

Duloxetine drug reduces painful chemotherapy-induced peripheral neuropathy in majority of patients

The antidepressant drug duloxetine, known commercially as Cymbalta, helped relieve painful tingling feelings caused by chemotherapy in 59 percent of patients, a new study finds. This is the first clinical trial to find an effective treatment for this pain.

4 Jun 2012

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Seattle Genetics, Inc. today announced that data from several clinical trials of ADCETRIS (brentuximab vedotin) will be presented at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2012 in Chicago, IL.

4 Jun 2012

Results from Janssen's ZYTIGA plus prednisone Phase 3 study on mCRPC

Results observed from pre-specified interim analyses of the randomized, placebo-controlled Phase 3 study, COU-AA-302, demonstrated that patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (ZYTIGA) plus prednisone showed a statistically significant improvement in radiographic progression-free survival (rPFS) and all secondary endpoints compared to patients treated with placebo plus prednisone.

4 Jun 2012

Reumofan Plus may have harmful pharmaceutical ingredients, warns FDA

The U.S. Food and Drug Administration is warning consumers that Reumofan Plus, marketed as a "natural" dietary supplement for pain relief and other serious conditions, contains several active pharmaceutical ingredients not listed on the label that could be harmful.

2 Jun 2012

Local anesthetic mixed with magnetized 'ferrofluids' may prevent rare complication of spinal anesthesia

An simple technique using local anesthetic mixed with magnetized "ferrofluids" may provide a new approach to preventing a rare but serious complication of spinal anesthesia, reports the June issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

2 Jun 2012

Cardinal Health to produce new AD diagnostic imaging agent, Amyvid

Cardinal Health today announced that it will manufacture and distribute Amyvid, Eli Lilly and Company's new diagnostic imaging agent that aids in the evaluation of adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline. The commercial launch of Amyvid is scheduled for June 1, 2012.

2 Jun 2012

Pisgah receives USPTO Notice of Allowance for drug abuse solution

Pisgah Laboratories, Inc. received Notice of Allowance from the United States Patent and Trademark Office for its patent application entitled "Opioid Salts and Formulations Exhibiting Anti-Abuse and Anti-Dose Dumping Properties."

2 Jun 2012

Exercise reduces expression of cytokines and alleviates neuropathic pain

Exercise helps to alleviate pain related to nerve damage (neuropathic pain) by reducing levels of certain inflammation-promoting factors, suggests an experimental study in the June issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

2 Jun 2012

New medication proves effective in slowing the spread of metastatic prostate cancer

A new medication proved effective in slowing the spread of metastatic prostate cancer, while helping to maintain the quality of life, in patients with advanced disease. The phase 3 study was unblinded midway, allowing patients receiving the placebo to instead take the drug because of the favorable results.

2 Jun 2012